Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563563 · ClinicalTrials.gov registry record · Phase 2
A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00563563 is a Phase 2 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT00563563, a Phase 2 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.
Interventions
- BEHAVIORAL Ancillary therapy
- DRUG NB32
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563563
The ClinicalTrials.gov registry entry for NCT00563563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ancillary therapy is the first listed.
NCT00563563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00563563 about?
NCT00563563 is a clinical study titled "A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent". The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.
What is the current status of trial NCT00563563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2007-10. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00563563?
The interventions under investigation include: Ancillary therapy (BEHAVIORAL), NB32 (DRUG).
Who is sponsoring clinical trial NCT00563563?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.